HomeCompareGRTS vs KMB

GRTS vs KMB: Dividend Comparison 2026

GRTS yields 6211.18% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRTS wins by $514736922231177.88M in total portfolio value
10 years
GRTS
GRTS
● Live price
6211.18%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$514736922231177.94M
Annual income
$498,935,081,000,370,800,000.00
Full GRTS calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — GRTS vs KMB

📍 GRTS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRTSKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRTS + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRTS pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRTS
Annual income on $10K today (after 15% tax)
$527,950.31/yr
After 10yr DRIP, annual income (after tax)
$424,094,818,850,315,200,000.00/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, GRTS beats the other by $424,094,818,850,315,200,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRTS + KMB for your $10,000?

GRTS: 50%KMB: 50%
100% KMB50/50100% GRTS
Portfolio after 10yr
$257368461115589.00M
Annual income
$249,467,540,500,185,400,000.00/yr
Blended yield
96.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

GRTS
Analyst Ratings
7
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$4.67
+14403.1% upside vs current
Range: $3.00 — $6.00
Altman Z
-9.7
Piotroski
1/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRTS buys
0
KMB buys
0
No recent congressional trades found for GRTS or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRTSKMB
Forward yield6211.18%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$514736922231177.94M$45.9K
Annual income after 10y$498,935,081,000,370,800,000.00$5,222.34
Total dividends collected$513674666624982.00M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$4.67$123.00

Year-by-year: GRTS vs KMB ($10,000, DRIP)

YearGRTS PortfolioGRTS Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$631,818$621,118.01$11,314$614.45+$620.5KGRTS
2$37,352,078$36,676,032.53$12,867$760.19+$37.34MGRTS
3$2,066,348,794$2,026,382,070.58$14,713$945.27+$2066.33MGRTS
4$106,978,454,906$104,767,461,696.78$16,924$1,181.90+$106978.44MGRTS
5$5,183,619,185,269$5,069,152,238,519.27$19,596$1,486.64+$5183619.17MGRTS
6$235,102,301,025,325$229,555,828,497,087.03$22,850$1,882.16+$235102301.00MGRTS
7$9,981,906,672,630,884$9,730,347,210,533,788.00$26,849$2,399.80+$9981906672.60MGRTS
8$396,781,870,195,426,800$386,101,230,055,711,700.00$31,812$3,083.36+$396781870195.40MGRTS
9$14,768,075,916,642,124,000$14,343,519,315,533,017,000.00$38,033$3,994.72+$14768075916642.08MGRTS
10$514,736,922,231,177,940,000$498,935,081,000,370,800,000.00$45,918$5,222.34+$514736922231177.88MGRTS

GRTS vs KMB: Complete Analysis 2026

GRTSStock

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Full GRTS Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this GRTS vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRTS vs SCHDGRTS vs JEPIGRTS vs OGRTS vs KOGRTS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.